#ASCO26 Program At A Glance for Saturday 30May2026

#ASCO26 Program At A Glance for Sunday 31May2026

#ASCO26 Program At A Glance for Monday 1Jun2026

#ASCO26 Program At A Glance for Friday 29May2026 and Tuesday 2Jun2026

Here are the #ASCO26 sessions at a glance, 2-page view.
Friday and Tuesday put together at the end, as they are shorter days and I can only include 4 images.
Full document here: cdn.bfldr.com/KOIHB2Q3/as/...

🔜 #GU26 @ascocancer.bsky.social

PFS benefit less than I would have expected…

“The median (95% CI) PFS was 14.7 (11.7–21.3) mos among pts in the concomitant ARPI cohort vs 12.5 (11.5–13.6) months in the no concomitant therapy. Ongoing follow-up… on long-term clinical outcomes, including OS.”

At @ascocancer.bsky.social #GU26, Robert Motzer presented phase 3 trial results that showed belzutifan + lenvatinib achieved superior PFS & ORR compared with cabozantinib in people with advanced #kidneycancer who progressed after immunotherapy. @mskcancercenter.bsky.social

🔗 https://bit.ly/4r4AYPD

Promising news from #GU26: Research led by @drchoueiri.bsky.social shows that adding #belzutifan to pembrolizumab adjuvant therapy prevented #ccRCC recurrence in high-risk patients better than pembrolizumab alone.

Learn more: https://bit.ly/3OxZdIE

EV + pembro in CisPt eligible pts
KEYNOTE-B15/EV-304 study
24-mo estimated EFS rate 79.4% vs 66.2%; HR 0.53
24-mo estimated OS rate 86.9% vs 81.3%; HR 0.65,
pCR rate (55.8% vs 32.5%)
#GU26

Images and descriptions of what's new on NEJM.org this week

New in the January 1, 2026, issue of NEJM:

Sacituzumab Tirumotecan in EGFR-TKI–Resistant NSCLC (OptiTROP-Lung04 phase 3 trial) nej.md/493hVjl

Osimertinib plus Chemotherapy in 𝘌𝘎𝘍𝘙-Mutated NSCLC (FLAURA2 phase 3 trial) nej.md/4opdBzC

These results compare favourably with those from the CARTITUDE-4 trial... more practical treatment option for patients with RRMM. However, its efficacy after prior daratumumab-based therapy, which is increasingly common, requires clarification.

At a median follow-up duration of 34.5 months, median PFS was unreached in the teclistamab–daratumumab group versus 18.1 months in the DPd or DVd group, with an estimated 36-month PFS of 83.4% versus 29.7% and an apparent plateauing of the curves beyond this landmark

The New England Journal of Medicine ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer A Research Summary based on Powles T et al. | 10.1056/NEJMoa2511885 | Published on October 20, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results and Research Summary: nej.md/3WIRtEg

The New England Journal of Medicine Disitamab Vedotin–Toripalimab in HER2-Expressing Urothelial Cancer A Research Summary based on Sheng X et al. | 10.1056/NEJMoa2511648 | Published on October 19, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

In HER2-expressing urothelial cancer, disitamab vedotin plus toripalimab doubled the median progression-free survival, increased the median overall survival, and reduced adverse events as compared with chemotherapy. Full RC48-C016 phase 3 trial results and Research Summary: nej.md/3W76VtS

De-escalation trials do not always need to be non-inferiority- A case for superiority design de-escalation trials in oncology Abstract. De-escalation trials in oncology have received increased attention recently because there is a growing concern that patients with cancer are bein

Bishal Gyawali makes "a case for using superiority design to test de-escalation strategies. This will avoid the limitations of non-inferiority design and make de-escalation strategies more efficient to test."

Original Article | Oct 30, 2025 European Study of Prostate Cancer Screening — 23-Year Follow-up Figure 2B. Prostate Cancer–Specific Mortality. The NEJM identity sits at the bottom.

At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: nej.md/42YYsg7

#MedSky #Oncology

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer | NEJM In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically r...

3️⃣ Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer (EMBARK trial) nej.md/4h8QpDc

𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲:
Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases (Newsweek) nej.md/47ztwoa

#ESMO25: Enzalutamide failed to deliver in high-risk localised #ProstateCancer in the ENZARAD trial, but improved OS, with leuprolide, in biochemically recurrent prostate cancer in the final OS analysis of EMBARK.
#ESMODailyReporter➡️ https://ow.ly/XCPX50XeO8K

Alison Tree

#ESMO25: 177Lu-PSMA-617 with ADT plus ARPI showed PFS benefit in hormone-sensitive #ProstateCancer (#HSPC) but no improvement seen with 177Lu-PSMA-617 vs docetaxel in castration-resistant prostate cancer (#mCRPC) after ARPI.
#ESMODailyReporter ➡️ https://ow.ly/2C0e50XeAoj

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303... Tarlatamab plus a PD-L1 inhibitor as maintenance after first-line chemo-immunotherapy showed a manageable safety profile with promising anticancer activity, supporting the ongoing phase 3 trial (NCT06...

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study www.thelancet.com/journals/lan...

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial Select patients with oligometastatic disease can be managed with serial metastasis-directed therapy with prolonged time off systemic therapy, favourable progression-free survival, and limited adverse ...

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial - The Lancet Oncology www.thelancet.com/journals/lan...

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC | NEJM Sacituzumab tirumotecan (sac-TMT) is an antibody–drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with EGFR-mutated non–small-cel...

Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC | New England Journal of Medicine www.nejm.org/doi/full/10....

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer | NEJM Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk fo...

Great result

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

#ESMO25: Atezolizumab prolonged DFS in #ctDNA+ muscle-invasive #BladderCancer in the IMvigor011 #ClinicalTrial, providing first evidence in support of minimal residual disease-guided adjuvant #immunotherapy in this setting.
#ESMODailyReporter ➡️ https://ow.ly/ythW50XeYRP

#ESMO25: Use of #ctDNA as a decision-making aid to guide adjuvant chemotherapy may not be ready for prime time in #ColonCancer as two #ClinicalTrials fail to meet their primary endpoints. Read more in the #ESMODailyReporter ➡️ https://ow.ly/OFmM50XeZaZ

#LiquidBiopsy

#ESMO25: Phase III FORTITUDE-101 #ClinicalTrial reports improved short-term survival with first-in-class FGFR2b inhibitor bemarituzumab added to chemotherapy to treat FGFR2b-overexpressing #Gastric or #GEJCancer.
More in the #ESMODailyReporter ➡️ https://ow.ly/C2MU50Xf08l

#ESMO25: First-line ivonescimab, a bispecific antibody targeting PD-1 and VEGF, plus chemotherapy improved progression-free survival vs tislelizumab plus chemotherapy in patients with squamous #NSCLC in the phase III HARMONi-6 trial.
#ESMODailyReporter 🔗 https://ow.ly/wl7X50XeA1o

#ESMO25: OS was significantly improved w/ the #ADC disitamab vedotin plus #immunotherapy w/ toripalimab vs chemotherapy in first-line advanced HER2-expressing #UrothelialCarcinoma in the RC48-C016 #ClinicalTrial.
#ESMODailyReporter 🔗 https://ow.ly/ZS9V50XeAsN

The combination of enfortumab vedotin (EV) – an antibody–drug conjugate – and pembrolizumab, before and after standard radical cystectomy and pelvic lymph node dissection, may be a potential new standard of care for cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC)
#esmo25

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274 Despite surgery, recurrence rates remain high in muscle-invasive urothelial carcinoma (MIUC). The phase III randomized, double-blind, multicenter CheckMate 274 trial comparing adjuvant nivolumab versu...

Five-year results confirm durable DFS benefit and consistent safety profile for adjuvant nivolumab in high-risk MIUC. Post-hoc exploratory ctDNA assessment identified patients at highest risk of recurrence. www.annalsofoncology.org/article/S092...

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study In metastatic hormone-sensitive prostate cancer (mHSPC), PTEN deficiency results in PI3K/AKT pathway activation, providing an independent proliferative drive, which cannot be suppressed by androgen re...

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study - Annals of Oncology www.annalsofoncology.org/article/S092...

#FLAURA2 analysis of exploratory subgroups shows mOS benefit in:

🧠 brain mets (40.9 v 29.7months)
🥃liver mets (36.6 vs 28months)
🦴bone mets (40.2 va 32.3 months)
🧬ctDNA positive (38.4 vs 32.5 months)

Confirms #FLAURA2 approch valid as a SOC in these groups #ESMO25 #LCSM

Kaplan–Meier curves for overall survival, assessed in a time-to-event analysis from randomization to death from any cause, in the combination group as compared with the leuprolide-alone group

In high-risk biochemically recurrent prostate cancer, enzalutamide plus leuprolide significantly improved overall survival as compared with leuprolide alone. Enzalutamide monotherapy had no significant benefit for survival. Full EMBARK phase 3 trial results: nej.md/4h8QpDc

#ESMO25